Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary
Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.
How this was made

The 30-second read
Why it matters
The earnings miss could trigger short‑term sell pressure, but restructuring and future product sales may provide upside later.
Market read
EBS earnings are a primary catalyst for its stock and may influence the broader biotech sector.
What to watch
Potential cost savings from the recent restructuring and upcoming product launches may mitigate the short‑term downside.
Background
Emergent BioSolutions filed its 10‑Q for Q3 2026, showing a sharp decline in NARCAN and medical countermeasure sales.
Ticker impact
Emergent BioSolutions reported Q3 2026 revenue of $110M and a net loss of $32.7M, a 52% revenue drop YoY.
downward pressure as the market prices in the earnings miss and loss
The earnings release reveals a 52% revenue decline and a $32.7M loss, which are material negative catalysts.
Market effects
The biotech/biopharma sector may see broader pressure as a peer reports weaker countermeasure sales.
U.S. biotech stocks could see modest pullback in the afternoon session.
Limited; the impact is primarily confined to U.S. listed biotech equities.
Counterpoint
If the market overreacts to the loss, a bounce could occur on the upcoming pipeline milestones.
Key entities
- companyEmergent BioSolutions Inc.
U.S. biotech firm focused on medical countermeasures.


